Jorge E. Cortes, MD, on Chronic Phase CML: Comparing Three Starting Doses of Ponatinib
EHA25 VirtualJorge E. Cortes, MD, of Georgia Cancer Center, discusses interim results from the OPTIC study, which showed a trend toward dose-dependent efficacy and safety, and may provide a refined understanding of the ponatinib benefit/risk profile and its relation to dose. Mature data from continued follow-up may support an alternate dosing regimen for patients with chronic phase chronic myeloid leukemia (Abstract S172).
Related Videos
Andrew H. Wei, MBBS, PhD, on AML: Venetoclax Plus Cytarabine in Older Patients
Andrew H. Wei, MBBS, PhD, of The Alfred Hospital, Monash University, discusses phase III data from the VIALE-C trial, which appear to support the use of venetoclax plus low-d...
Efstathios Kastritis, MD, on Amyloidosis: Daratumumab Plus Cyclophosphamide, Bortezomib, and Dexamethasone
Efstathios Kastritis, MD, of the University of Athens, discusses phase III findings of the Andromeda study. Adding daratumumab to cyclophosphamide, bortezomib, and dexamethas...
Courtney D. DiNardo, MD, on AML: Venetoclax and Azacitidine for Treatment-Naive Patients
Courtney D. DiNardo, MD, of The University of Texas MD Anderson Cancer Center, discusses data from her study of treatment-naive, predominantly older patients with acute myelo...
Anthony Moorman, PhD, on ALL: Improving Outcomes With a Tyrosine Kinase Inhibitor Plus Chemotherapy
Anthony Moorman, PhD, of Newcastle University, discusses preliminary data showing high-risk patients with acute lymphoblastic leukemia and ABL-class mutations may ha...
Elizabeth H. Phillips, MD, on DLBCL: Inotuzumab Ozogamicin Plus Chemotherapy in Front-Line Setting
Elizabeth H. Phillips, MD, of the University of Manchester and The Christie Hospital, discusses phase II findings showing inotuzumab ozogamicin plus rituximab, cyclophosphami...
